Riley J P, Pestano G A, Hosford K, Francis C, Xie J M, Mugyenyi P, Kataaha P, Katongole-Mbidde E, Anokbonggo W W, Guyden J
Department of Biology, City College, City University of New York, New York, USA.
Arch Virol. 1995;140(8):1393-404. doi: 10.1007/BF01322666.
Synthetic peptides comprising the predicted principal neutralizing determinant (PND) in new African and North American HIV-1 clones were tested in ELISA for reactivity with ninety six serum samples from asymptomatic donors in six selected localities in Uganda. Irrespective of the geographical origin of the samples, the majority of the test sera cross-reacted at high intensities with the peptides derived from the North American clone, BRT3.6 (Group B), the Ugandan clone, CUG045, (Group C), and the Romanian clone, FRMA (Group F). The frequency of reactivity of the peptides from BRT3.6, CUG045, and FRMA were within the ranges of 57-100%, 50-100%, and 57-100%, respectively, for the sera collected from these disparate localities. In contrast to these findings, the V3 peptides derived from the other Ugandan isolates showed a more restricted pattern of reactivity with the same serum samples: AUG06c (1-63%), DUG23c (2%), and DUG044 (38-87%). The results from ELISA inhibition assay indicated that the V3 peptide from BRT 3.6, CUG045, and FRMA express closely related antigenic specificities quite distinct from those in AUG06c and DUG044. The residues comprising the PND in BRT 3.6, CUG045, and FRMA appear to be well conserved in the HIV-1 subtypes prevalent in the selected Ugandan locales.
在酶联免疫吸附测定（ELISA）中，对包含新的非洲和北美HIV-1克隆中预测的主要中和决定簇（PND）的合成肽，与来自乌干达六个选定地区无症状供体的96份血清样本进行反应性测试。无论样本的地理来源如何，大多数测试血清都与源自北美克隆BRT3.6（B组）、乌干达克隆CUG045（C组）和罗马尼亚克隆FRMA（F组）的肽发生高强度交叉反应。对于从这些不同地区收集的血清，来自BRT3.6、CUG045和FRMA的肽的反应频率分别在57 - 100%、50 - 100%和57 - 100%范围内。与这些发现相反，源自其他乌干达分离株的V3肽与相同血清样本的反应模式更为受限：AUG06c（1 - 63%）、DUG23c（2%）和DUG044（38 - 87%）。酶联免疫吸附抑制试验结果表明，来自BRT 3.6、CUG045和FRMA的V3肽表达的抗原特异性与AUG06c和DUG044中的抗原特异性密切相关且截然不同。在选定的乌干达地区流行的HIV-1亚型中，BRT 3.6、CUG045和FRMA中构成PND的残基似乎高度保守。
